LIDOCAINE HCI AND DEXTROSE
LIDOCAINE HCI AND 5% DEXTROSE INJECTION USP 2g (4mg/mL) 500mL BAG
Approved
Approval ID
861ba61a-5835-3b9a-e053-2a91aa0aee5e
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Dec 15, 2022
Manufacturers
FDA
HF Acquisition Co LLC, DBA HealthFirst
DUNS: 045657305
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
LIDOCAINE HCI AND DEXTROSE
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code51662-1302
Application NumberNDA018461
Product Classification
M
Marketing Category
C73594
G
Generic Name
LIDOCAINE HCI AND DEXTROSE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 15, 2022
FDA Product Classification
INGREDIENTS (4)
DEXTROSE MONOHYDRATEInactive
Quantity: 50 mg in 1 mL
Code: LX22YL083G
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
LIDOCAINE HYDROCHLORIDEActive
Quantity: 4 mg in 1 mL
Code: V13007Z41A
Classification: ACTIB